The FDA has approved the first prescription, at-home neuromodulation therapy for individuals with major depressive disorder ...

CORAL SPRINGS, Fla., Jan. 12, 2026 /PRNewswire/ -- Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today announced that the U.S. Food and ...

The wearable device delivers electrical impulses through a headset that can be administered by the patient at home under ...

Abbott’s five-year data highlighted neuromodulation therapies’ role in reducing healthcare and patient burdens associated ...

This post was co-authored by Abigail Ramos and Robert T. Muller, Ph.D. With the development of new neuro-technology and emerging research on the function of the brain, the treatment of mental illness ...

With its expansion into St. Louis, Restore Brain continues its mission to broaden access to advanced psychiatric treatments ...

The International Neuromodulation Society (INS) journal Neuromodulation: Technology at the Neural Interface is publishing expert, evidence-based guidance on the safe and efficient use of ...

Magnus Medical, Inc., the company behind SAINT®, the first and only FDA-cleared, rapid-remission therapy for Major Depressive Disorder (MDD), today announced that the Centers for Medicare & Medicaid ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and ...

PARK CITY, Utah--(BUSINESS WIRE)--BlueWind Medical, Ltd., a leader in implantable Tibial Neuromodulation (iTNM) and developer of the Revi® System, a patient-centric solution for urge urinary ...